Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph V. Boccia, MD, Stephen J. Noga, MD, PhD, Donald S. Gravenor, MD, Dipti Patel-Donnelly, MD, Robert S. Siegel, MD, Tarun Kewalramani, MD, Edward J. Gorak, DO, MS, Regina A. Swift, RN, Debra Mayo, PharmD, MHA

Blood (2011) 118 (21): 1857.

https://doi.org/10.1182/blood.V118.21.1857.1857

Published: 2011

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

James R. Berenson, MD, Ori Yellin, MD, Alan D. Cartmell, MD, Thomas B. S. Woliver, MD, Marshall S. Flam, MD, Youram Nassir, MD, Robert Vescio, MD, Regina A. Swift, RN

Blood (2010) 116 (21): 3044.

https://doi.org/10.1182/blood.V116.21.3044.3044

Published: 2010

Journal Articles

A Multicenter Randomized Clinical Trial Comparing a Powered Bone Marrow Biopsy System and Manual Bone Marrow Biopsy Procedures.

James R. Berenson, MD, Ori Yellin, MD, Deanna Bojanower, ANP-C, Croopnick Jonathan, MD, David Aboulafia, MD, Gargi Upadhyaya, MD, Brent Blumenstein, PhD

Blood (2010) 116 (21): 3840.

https://doi.org/10.1182/blood.V116.21.3840.3840

Published: 2010

Journal Articles

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Youram Nassir, MD, Shellie Rothstein, Regina A. Swift

Blood (2009) 114 (22): 1855.

https://doi.org/10.1182/blood.V114.22.1855.1855

Published: 2009

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ravi Patel, MD, Chien-Shing Chen, MD, Ralph Vincent Boccia, MD, Donald Colbourn, MD, Honghao (Hank) Yang, MD, PhD, Varun Gupta, MD, George F. Geils, Jr., MD, Youram Nassir, MD, Jacqueline Hilger, MS, Regina A. Swift

Blood (2009) 114 (22): 4936.

https://doi.org/10.1182/blood.V114.22.4936.4936

Published: 2009

Journal Articles

A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices.

James R. Berenson, MD, David J. Donahue, Ori Yellin, MD, Gargi Upadhyaya, MD, Youram Nassir, MD, Regina A. Swift

Blood (2009) 114 (22): 4234.

https://doi.org/10.1182/blood.V114.22.4234.4234

Published: 2009

Journal Articles

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

James R. Berenson, MD, Ori Yellin, MD, Donald Woytowitz, MD, Marshall S. Flam, MD, Alan Cartmell, MD, Ravi Patel, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3602.

https://doi.org/10.1182/blood.V110.11.3602.3602

Published: 2007

Journal Articles

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Marshall S. Flam, MD, Siu-Fun Wong, PharmD, Olcay Batuman, MD, Mehdi M. Moezi, MD, Donald Woytowitz, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3606.

https://doi.org/10.1182/blood.V110.11.3606.3606

Published: 2007

Journal Articles

Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.

James R. Berenson, MD, Ori Yellin, MD, John Crowley, PhD, Herbert Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 4842.

https://doi.org/10.1182/blood.V110.11.4842.4842

Published: 2007

NARROW

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

A Multicenter Randomized Clinical Trial Comparing a Powered Bone Marrow Biopsy System and Manual Bone Marrow Biopsy Procedures.

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices.

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only